Having investigated around 60 potential epigenetic-related drug targets, the UK's CellCentric Ltd. believes it has found one that is a first-in-class candidate for treatment-resistant prostate cancer and is heading to the clinic with $26m in new funds.
The Cambridge-headquartered privately held biotech has raised all the cash from one of its existing backers - Morningside Venture Investments – to finance clinical testing of CCS1477, an inhibitor of the twin histone acetyl transferase proteins p300 and CBP
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?